DiaMedica Therapeutics Inc.
HealthcareNASDAQ:DMAC · NASDAQ Capital Market
+$0.19 today
Vol 0.10M · Avg 0.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-58.4%
avg -95.0%
ROIC
-61.0%
avg -92.4%
ROA
-53.4%
avg -128.0%
Analysis
ROA is currently the strongest return metric at -53.4% versus its period average of -128.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dietrich John Pauls | President, Chief Executive Officer & Director | $1.07M | — | 55 | $600,000.00 | 1.11% |
Julie Krop | Chief Medical Officer | $675,668.00 | — | 60 | $0.00 | <0.01% |
Scott Kellen | Chief Financial Officer & Corporate Secretary | $609,870.00 | — | 61 | $225,000.00 | 0.42% |
Dominic R. Cundari | Chief Commercial Officer | — | — | 75 | $15,000.00 | 0.03% |
Ambarish Shah | Chief Technology Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
19
$30.39M
Sells
0
$0.00
Net Sentiment
+$30.39M
Net buying
Most Active
STAHLBERG JAN
17 transactions
1–10 of 19
Analysis
Insiders reported 19 buys worth $30.39M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $30.39M. STAHLBERG JAN was the most active insider with 17 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$889.71M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
I-Mab
IMAB
$235.66M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
Genelux Corporation
NASDAQ:GNLX
$111.35M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages DMAC?
DiaMedica Therapeutics Inc. (DMAC) lists 5 active executives. The top listed executive is Dietrich John Pauls, President, Chief Executive Officer & Director.
Are DMAC insiders buying or selling?
Recent insider activity shows net buying of $65.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.